Nanovesicular carrier-based formulation for skin cancer targeting: evaluation of cytotoxicity, intracellular uptake, and preclinical anticancer activity

References

• Vineis P. Definition and classification of cancer: monothetic or polythetic? Theor Med 1993;14:249–56
   PubMedGoogle Scholar
• Prendergast GC, Jaffee EM. Cancer immunologists and cancer cell biologists: why we didn’t talk then but need to now. Cancer Res 2007;67:3500–5
   PubMed Web of Science ®Google Scholar
• Fadeyi OO, Adamson ST, Myles EL, et al. Novel fluorinated acridone derivatives. Part 1: synthesis and evaluation as potential anticancer agents. Bioorg Med Chem Lett 2008;18:4172–6
   PubMed Web of Science ®Google Scholar
• Schalhorn A, Kühl M. Clinical pharmacokinetics of fluorouracil and folinic acid. Semin Oncol 1992;19:82–92
   PubMed Web of Science ®Google Scholar
• Kalra AV, Campbell RB. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer 2007;97:910–18
   PubMed Web of Science ®Google Scholar
• Deepa G, kumar NA, Pillai JJ, et al. Polymer nanoparticles – a novel strategy for administration of paclitaxel in cancer chemotherapy. Curr Med Chem 2012;19:6207–13
   PubMed Web of Science ®Google Scholar
• Angels FK, Sparreboom A, Mathot RAA, et al. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005;93:173–7
   PubMed Web of Science ®Google Scholar
• Watterson J, Toogood I, Nieder M, et al. Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 1994;74:3034–41
   PubMed Web of Science ®Google Scholar
• Leung IF, Tannock AM, Oza A, et al. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast. Cancer J Clin Oncol 1999;17:3082–90
   PubMed Web of Science ®Google Scholar
• Khanna A, Walker GR, Livingstone AS, et al. Is adjuvant 5-FU-based chemoradiotherapy for resectable pancreatic adenocarcinoma beneficial? A meta-analysis of an unanswered question. J Gastrointest Surg 2006;10:689–97
   PubMed Web of Science ®Google Scholar
• Sabitha M, Sanoj RN, Nair A, et al. Development and evaluation of 5-fluorouracil loaded chitin nanogels for treatment of skin cancer. Carbohydr Polym 2013;91:48–57
   PubMed Web of Science ®Google Scholar
• Singh BN, Singh RB, Singh J. Effects of ionization and penetration enhancers on the transdermal delivery of 5-fluorouracil through excised human stratum corneum. Int J Pharm 2005;298:98–107
   PubMed Web of Science ®Google Scholar
• Moore AY. Clinical applications for topical 5-fluorouracil in the treatment of dermatological disorders. J Dermatolog Treat 2009;20:328–35
   PubMed Web of Science ®Google Scholar
• Lowenthal RM, Eaton K. Toxicity of chemotherapy. Hematol Oncol Clin North Am 1996;10:967–90
   PubMed Web of Science ®Google Scholar
• Krebs HB. The use of topical 5-fluorouracil in the treatment of genital condylomas. Obstet Gynecol Clin North Am 1987;14:559–68
   PubMed Web of Science ®Google Scholar
• Paolino D, Cosco D, Muzzalupo R, et al. Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer. Int J Pharm 2008;353:233–42
   PubMed Web of Science ®Google Scholar
• Alvi IA, Madan J, Kaushik D, et al. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, characterization, in vitro release, and cytotoxicity analysis. Anticancer Drugs 2011;22:774–82
   PubMed Web of Science ®Google Scholar
• Xiao YY, Liu F, Chen ZP, et al. Microemulsion-based gel of fluorouracil for transdermal delivery. Yao Xue Xue Bao 2010;45:1440–6
   PubMedGoogle Scholar
• Gupta RR, Jain SK, Varshney M. AOT water-in-oil microemulsions as a penetration enhancer in transdermal drug delivery of 5-fluorouracil. Colloids Surf B Biointerfaces 2005;41:25–32
   PubMed Web of Science ®Google Scholar
• Ghorab MM, Zia H, Luzzi LA. Preparation of controlled release anticancer agents. I: 5-fluorouracil-ethyl cellulose microspheres. J Microencapsul 1990;7:447–54
   PubMed Web of Science ®Google Scholar
• El Maghraby GM, Williams AC, Barry BW. Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in vitro. J Pharm Pharmacol 2001;53:1069–77
   PubMed Web of Science ®Google Scholar
• Liu FT, He R, Gao F, et al. Modification and transdermal absorption of 5-fluorouracil ethosomes. China Pharmacy 2008;25:1938–40
   Google Scholar
• Wo Y, Zhang Z, Zhang Y, et al. Preparation of ethosomes and deformable liposomes encapsulated with 5-fluorouracil and their investigation of permeability and retention in hypertrophic scar. J Nanosci Nanotechnol 2011;11:7840–7
   PubMed Web of Science ®Google Scholar
• Ramachandran S, Quist AP, Kumar S, et al. Cisplatin nanoliposomes for cancer therapy: AFM and fluorescence imaging of cisplatin encapsulation, stability, cellular uptake, and toxicity. Langmuir 2006;22:8156–62
   PubMed Web of Science ®Google Scholar
• Matthäus C, Kale A, Chernenko T, et al. New ways of imaging uptake and intracellular fate of liposomal drug carrier systems inside individual cells, based on Raman microscopy. Mol Pharm 2008;5:287–93
   PubMed Web of Science ®Google Scholar
• Utreja P, Jain S, Tiwary AK. Novel drug delivery systems for sustained and targeted delivery of anticancer drugs: current status and future prospects. Curr Drug Deliv 2010;7:152–61
   PubMedGoogle Scholar
• Batheja P, Sheihet L, Kohn J, et al. Topical drug delivery by a polymeric nanosphere gel: formulation optimization and in vitro and in vivo skin distribution studies. J Control Release 2011;149:159–67
   PubMed Web of Science ®Google Scholar
• Puri R, Jain S. Ethogel topical formulation for increasing the local bioavailability of 5-fluorouracil: a mechanistic study. Anticancer Drugs 2012;23:923–34
   PubMed Web of Science ®Google Scholar
• Dubey V, Mishra D, Jain NK, et al. Dermal and transdermal delivery of an anti-psoriatic agent via ethanolic liposomes. J Control Release 2007;123:148–54
   PubMed Web of Science ®Google Scholar
• Washington C. Evaluation of the non-sink dialysis method for the measurement of drug release from colloids effect of drug partition. Int J Pharm 1989;56:71–4
   Web of Science ®Google Scholar
• Jain S, Jain P, Umamaheshwari RB, et al. Transfersomes – a novel vesicular carrier for enhanced transdermal delivery: development, characterization, and performance evaluation. Drug Dev Ind Pharm 2003;29:1013–26
   PubMed Web of Science ®Google Scholar
• Mutimier MN, Reffkin C, Hill JA, et al. Modern ointment base technology II. J Am Pharm Assoc 1956;45:212–18
   Google Scholar
• Yuan G, Rong L, Duanyun S, et al. Determination of 5-fluorouracil in human plasma by high-performance liquid chromatography (HPLC). Trans Tianjin Univ 2010;16:167–73
   Google Scholar
• Avis IM, Jett M, Boyle T, et al. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J Clin Invest 1996;97:806–13
   PubMed Web of Science ®Google Scholar
• U.S. Pharmacopeia. The United States Pharmacopeia, USP 30/The National Formulary, NF 25. Rockville (MD): U.S. Pharmacopeial Convention, Inc.; 2007
   Google Scholar
• Liu W, Li X, Wong YS, et al. Selenium nanoparticles as a carrier of 5-fluorouracil to achieve anticancer synergism. ACS Nano 2012;6:6578–91
   PubMed Web of Science ®Google Scholar
• Palmgren MG. Acridine orange as a probe for measuring pH gradient across membrane: mechanism and limitations. Anal Biochem 1991;192:316–21
   PubMed Web of Science ®Google Scholar
• Lovelace MD, Cahill DM. A rapid cell counting method utilising acridine orange as a novel discriminating marker for both cultured astrocytes and microglia. J Neurosci Methods 2007;165:223–9
   PubMed Web of Science ®Google Scholar
• Arias JL. Novel strategies to improve the anticancer action of 5-fluorouracil by using drug delivery systems. Molecules 2008;13:2340–69
   PubMed Web of Science ®Google Scholar
• Dickinson BC, Chang CJ. Chemistry and biology of reactive oxygen species in signaling or stress responses. Nat Chem Bio 2011;7:504–11
   PubMed Web of Science ®Google Scholar
• Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat Chem Biol 2008;4:278–86
   PubMed Web of Science ®Google Scholar
• Irani K, Xia Y, Zweier JL, et al. Goldschmidt–Clermont, mitogenic signaling mediated by oxidants in Ras-transformed fibroblasts. Science 1997;275:649–1652
   PubMed Web of Science ®Google Scholar
• Ramsey MR, Sharpless NE. ROS as a tumour suppressor? Nat Cell Biol 2006;8:1213–15
   PubMed Web of Science ®Google Scholar
• Takahashi A, Ohtani N, Yamakoshi K, et al. Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence. Nat Cell Biol 2006;8:1291–7
   PubMed Web of Science ®Google Scholar
• Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer 2004;40:1934–40
   PubMed Web of Science ®Google Scholar
• Wan CP, Myung E, Lau BH. An automated micro-fluorometric assay for monitoring oxidative burst activity of phagocytes. J Immun Methods 1993;159:131–8
   PubMed Web of Science ®Google Scholar
• Tsuji T, Sugai T. Topically administered fluorouracil in psoriasis. Arch Dermatol 1972;105:208–12
   PubMed Web of Science ®Google Scholar
• Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000;42:S25–8
   PubMed Web of Science ®Google Scholar
• Das RK, Ghosh S, Sengupta A, et al. Inhibition of DMBA/croton oil-induced two-stage mouse skin carcinogenesis by diphenylmethyl selenocyanate. Eur J Cancer Prev 2004;13:411–17
   PubMed Web of Science ®Google Scholar
• Subramanian V, Venkatesan B, Tumala A. Topical application of gallic acid suppresses the 7,12-DMBA/croton oil induced two step skin carcinogenesis by modulating anti-oxidants and MMP-2/MMP-9 in Swiss albino mice. Food Chem Toxicol 2014;66:44–55
   PubMed Web of Science ®Google Scholar
• Das RK, Bhattacharya S. Inhibition of DMBA–croton oil two-stage mouse skin carcinogenesis by diphenylmethyl selenocyanate through modulation of cutaneous oxidative stress and inhibition of nitric oxide production. Asian Pac J Cancer Prev 2004;5:151–8
   PubMedGoogle Scholar